Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

reparixin

Known as: (R)-2-(4-isobutylphenyl)propionylmethanesulfonamide, Benzeneacetamide, Alpha-methyl-4-(2-methylpropyl)-N- (methylsulfonyl)- (alphaR)-, Repertaxin 
An orally available inhibitor of CXC chemokine receptor types 1 (CXCR1) and 2 (CXCR2), with potential antineoplastic activity. Upon administration… Expand
National Institutes of Health

Related topics

Related topics

1 relation
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2–Negative Metastatic Breast Cancer
Purpose: Chemokine receptor 1 (CXCR1) is recognized as an actionable receptor selectively expressed by breast cancer stem cells… Expand
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2011
Highly Cited
2011
A Self-Propagating Matrix Metalloprotease-9 (MMP-9) Dependent Cycle of Chronic Neutrophilic Inflammation
Background Chronic neutrophilic inflammation is a poorly understood feature in a variety of diseases with notable worldwide… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
Highly Cited
2010
Highly Cited
2010
CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts.
Recent evidence suggests that breast cancer and other solid tumors possess a rare population of cells capable of extensive self… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Prostaglandin mediates IL-23/IL-17-induced neutrophil migration in inflammation by inhibiting IL-12 and IFNγ production
IL-23/IL-17-induced neutrophil recruitment plays a pivotal role in rheumatoid arthritis (RA). However, the mechanism of the… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2008
Highly Cited
2008
CXCR2-specific chemokines mediate leukotriene B4-dependent recruitment of neutrophils to inflamed joints in mice with antigen-induced arthritis.
OBJECTIVE To investigate the mechanism underlying neutrophil migration into the articular cavity in experimental arthritis and… Expand
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusion.
BACKGROUND Ischemia/reperfusion (I/R) injury after organ transplantation is a major cause of delayed graft function. Following I… Expand
Is this relevant?
Highly Cited
2005
Highly Cited
2005
2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors.
The CXC chemokine CXCL8/IL-8 plays a major role in the activation and recruitment of polymorphonuclear (PMN) cells at… Expand
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Inhibition of interleukin-8 (CXCL8/IL-8) responses by repertaxin, a new inhibitor of the chemokine receptors CXCR1 and CXCR2.
Repertaxin is a new non-competitive allosteric blocker of interleukin-8 (CXCL8/IL-8) receptors (CXCR1/R2), which by locking CXCR1… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury.
The chemokine CXC ligand 8 (CXCL8)/IL-8 and related agonists recruit and activate polymorphonuclear cells by binding the CXC… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Repertaxin, a novel inhibitor of rat CXCR2 function, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury
Neutrophils are thought to play a major role in the mediation of reperfusion injury. CXC chemokines are known inducers of… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE